Skip to Content
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 10/10/23

Past CIP Initiatives

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

PAR-20-277: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

PAR-20-276: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

PA-19-112: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)

PA-19-111: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)

PAR-18-841: Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)

PAR-20-295: Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)

PAR-19-363: Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

PAR-16-089: Imaging and Biomarkers for Early Detection of Aggressive Cancer (U01)

PAR-15-334: Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21)

PAR-15-331: Advanced Development of Informatics Technologies for Cancer Research and Management (U24)

PA-16-040: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21)s

PAR-15-332: Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01)

PA-14-155: Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R01)

PAR-14-085: Revision applications for research on metabolic reprogramming to improve immunotherapy (R01)

PAR-18-530: Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)

PAR-18-919: Quantitative Imaging Tools and Methods for Cancer Response Assessment (R01 Clinical Trial Optional)

PAR-18-629: Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

PAR-18-560: Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

PAR-18-252: Image-guided Drug Delivery (R01)

PAR-18-248: Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)

PAR-18-011: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)

PA-17-243: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21)

PA-17-239: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01)

PAR-16-385: Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine(U24)

PAR-14-166: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)

PAR-15-266: Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24)

Source: FOA Page

  • Release Date: June 11, 2015
  • Application Receipt Date: Nov 17, 2015; Jun 14, 2016; Nov 17, 2016; June 14, 2017; Nov 17, 2017; Jun 14, 2018
  • Expiration Date: Jun 15, 2018

  • Contacts:
    Huiming Zhang, Ph.D., NCI
    Phone: 240-276-5979
    Email: zhanghui@mail.nih.gov

    Cheryl L. Marks, Ph.D., NCI
    Phone: 240-276-6217
    Email: marksc@mail.nih.gov

    Richard V. Mazurchuk, Ph.D., NCI
    Phone: 240-276-7126
    Email: mazurchukrv@mail.nih.gov

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve correlation of results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations.

Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients’ malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

Back to top

PAR-14-013: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21) — Reissued

  • Release Date: March 05, 2014
  • Application Receipt Date: June 30, 2014; October 10, 2014; February 9, 2015, June 9, 2015; October 9, 2015; February 9, 2015; June 9, 2016; October 11, 2016; February 9, 2017, by 5:00 PM local time of applicant organization.
  • Expiration Date: February 10, 2017

  • Contacts:

    Imaging trials:
    Lori A. Henderson, Ph.D., NCI
    Phone: 240-276-5930
    Email: hendersonlori@mail.gov

    Frank I. Lin, M.D., NCI
    Phone: 240-276-5932
    Email: frank.lin2@nih.gov

    Image-Guided Intervention [IGI] trials:
    Keyvan Farahani, Ph.D., NCI
    Phone: 240-276-5921
    Email: farahank@mail.nih.gov

    Radiation Therapy related trials:
    Bhadrasain Vikram, M.D., NCI
    Phone: 240-276-5690
    Email: vikramb@mail.nih.gov

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI’s National Clinical Trials Network.

Back to top

PAR-13-185: Image-guided Drug Delivery in Cancer (R01)

  • Release Date: May 14, 2013
  • Application Receipt Date: June 19, 2013; November 19, 2013; June 19, 2014; November 19, 2014; June 19, 2015; November 19, 2015
  • Expiration Date: November 20, 2015

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 240-276-5921

    Please see the FOA for a complete list of contacts.

This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

Back to top

PAR-13-169: Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

  • Release Date: May 14, 2013
  • Application Receipt Date: Standard dates apply: see http://grants.nih.gov/grants/funding/submissionschedule.htm
  • Expiration Date: May 8, 2016

  • Contacts:
    Houston Baker, Ph.D.
    Phone: 240-276-5908
    Email: bakerhou@mail.nih.gov

    Please see the FOA for a complete list of contacts.

This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either preclinical or clinical in vivo imaging systems and/or methods that are designed to solve a targeted cancer problem. The proposed imaging system/methods may include single or multi-modality in vivo imaging and spectroscopy systems, image-guided and drug delivery systems, image analysis, and related research resources. This FOA may also include, as a secondary goal, support for other laboratory imaging or reference methods as required to validate the performance of the proposed in vivo imaging system and/or methods. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others: (a) current commercially supported imaging systems/methods, (b) next-generation imaging systems/methods, (c) quality assurance and quality control methods, (d) validation and correlation studies, (e) quantitative imaging methods, and (f) related research resources. Because appropriate applications must be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. The partnerships on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their proposed imaging system/methods to solve a targeted cancer problem. This FOA will support clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. This FOA will not support commercial production, or basic research projects that do not emphasize translational development and optimization of the methods for a targeted cancer problem.

Back to top

PAR-11-216: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)

  • Release Date: May 24, 2011
  • Application Receipt Date: See below
  • Expiration Date: March 14, 2014

  • Contacts:

    Imaging trials:
    Lalitha K. Shankar, M.D., Ph.D., NCI
    Phone: 240-276-6510
    Email: shankarl@mail.nih.gov

    Frank I. Lin, M.D., NCI
    Phone: 240-276-5932
    Email: frank.lin2@nih.gov

    Image-Guided Intervention trials:
    Keyvan Farahani, Ph.D., NCI
    Phone: 240-276-5921
    Email: farahank@mail.nih.gov

    Radiation Therapy trials:
    Bhadrasain Vikram, M.D., NCI
    Phone: 240-276-5690
    Email: vikramb@mail.nih.gov

  • Application Receipt/Submission Date(s): July 27, 2011; November 10, 2011; March 13, 2012; July 11, 2012; November 13, 2012; March 13, 2013; July 11, 2013; November 13, 2013; March 13, 2014, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Center and/or Cooperative Groups.

See full description in NIH Guide: PAR-11-216.

Back to top

PAR-11-150: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)

  • Release Date: March 14, 2011
  • Application Receipt Date: Standard dates
  • Expiration Date: May 8, 2014

  • Contacts:
    Robert J. Nordstrom, Ph.D.
    Email: nordstrr@mail.nih.gov
    Phone: 240-276-5934

The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.

See the CIP QIN website for a description of the program.

No set-aside

See full description in NIH Guide: PAR-11-150

Clarification of Scope and Requirements of PAR-11-150: NOT-CA-11-011

Back to top

PA-10-080 and PA-10-079: Image-Guided Interventions (STTR [R41/R42] & SBIR [R43/R44])

  • Release Date: January 08, 2010
  • Application Receipt Date: Multiple dates, see announcements.
  • Expiration Date: January 8, 2013

  • Contacts:
    David Beylin, M.S., NCI
    Phone: 301-496-0079
    Email: beylind@mail.nih.gov

These Funding Opportunity Announcements (FOA) support the development and clinical validation of systems for image-guided interventions (IGIs) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; the validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals..

See full description in NIH Guide: STTR (R41/R42) PA-10-080; SBIR (R43/44) PA-10-079

Back to top

PA-09-253: Image-guided Drug Delivery in Cancer (R01)

  • Release Date: August 13, 2009
  • Application Receipt Date: Standard dates
  • Expiration Date: May 8, 2013

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 240-276-5921

The NCI encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This initiative will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first in human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this initiative.

No set-aside

See full description in NIH Guide: PA-09-253

Back to top

PAR-09-157: In vivo Cellular and Molecular Imaging Centers (ICMICs) (P50)

  • Release Date: April 13, 2009
  • Application Receipt Date: October 28, 2009, October 28, 2010, October 28, 2011
  • Expiration Date: October 29, 2011

  • Contacts:
    Anne Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-496-9531

The Cancer Imaging Program, and the Division of Cancer Diagnosis and Treatment, at the National Cancer Institute (NCI), invite new or renewal (competing) applications for P50 Research Center Grants for In vivo Cellular and Molecular Imaging Centers (ICMICs). The program will fund the 5-year P50 ICMIC grants to support interdisciplinary scientific teams conducting cutting-edge cancer molecular imaging research. ICMIC funding is designed to: (1) support innovative cancer molecular imaging research projects; (2) support unique core facilities; (3) enable the awardees to initiate pilot research in new promising directions; and (4) provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging.

Letters of Intent Receipt Dates: September 28, 2009, September 28, 2010, September 28, 2011

No set-aside

See full description in NIH Guide: PAR-09-157

Back to top

PAR-08-225: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)

  • Release Date: August 03, 2008
  • Application Receipt Date: Standard dates
  • Expiration Date: May 8, 2011

  • Contacts:
    Robert J. Nordstrom, Ph.D.
    Email: nordstrr@mail.nih.gov
    Phone: 240-276-5934

The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees will form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.

No set-aside

See full description in NIH Guide: PAR-08-225

Back to top

PAR-08-147: Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21) (NCI)

  • Release Date: April 15, 2008
  • Expiration Date: April 12, 2011

  • Contacts:
    Barbara Galen, M.S.N., C.R.N.P., C.N.M.T., NCI
    Phone: 301-594-5225
    Email: bgalen@mail.nih.gov

    Lalitha Shankar, M.D., NCI
    Phone: 301-496-9531
    Email: shankarl@mail.nih.gov

    Keyvan Farahani, Ph.D., NCI
    Phone: 301-451-2651
    Email: farahank@mail.nih.gov

The goal of this Funding Opportunity Announcement (FOA) is to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. The rapid translation of promising discoveries in the fields of imaging probes, methodologies, technologies and image-guided therapies to clinical practice requires timely support. This FOA will provide investigators with support for either pilot (Phase I and II) cancer clinical trials, or patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) studies, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or Cooperative Groups.

Mechanism of support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism

See full description in NIH Guide: PAR-08-147

For instructions on the inclusion of clinical protocols in the PAR-08-147 application, see NOT-CA-10-019

Back to top

PAR-08-025: Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)

  • Release Date: November 19, 2007
  • Expiration Date: November 10, 2010

  • Contacts:
    Heng Xie, Ph.D., NCI
    Phone: 301-496-8866
    Email: xiehe@mail.nih.gov

This Funding Opportunity Announcement (FOA) is intended to promote translational research in new agent/modality development with timely exploitation of new cancer-relevant therapeutic and/or preventive strategies that involve defined molecular targets. Applications are solicited for pilot clinical trials exploring individual anticancer agents/modalities and/or their combinations in the context of specific molecular targets. Applicants may propose Phase 0, Phase I, Phase II, and/or other pilot cancer clinical trials. In addition, patient monitoring and laboratory correlative studies related to clinical trials may be proposed. Applications that explore complementary and alternative approaches for cancer prevention and/or treatment are also encouraged. Clinical trials proposed may be oriented on AIDS-associated malignancies and cancer-related nutritional interventions. Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application.

Mechanism of Support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism

See full description in NIH Guide: PAR-08-025

Back to top

RFA-CA-08-002: Network for Translational Research (NTR): Optical Imaging in Multimodal Platforms (U54)

This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI) is an open competition initiative, designed to continue the efforts of the NCI to develop and translate cancer-relevant optical imaging technologies as a part of an overall imaging program for early cancer detection, diagnosis, therapeutic response, drug development, and image-guided therapy. This FOA stems from the previous initiative on optical imaging technology. However, the program structure and goals of the current FOA differ from those of the original program. Accordingly, all responses to this FOA will be considered new applications, with the main objective being to accelerate the translational research of in vivo multimodal imaging and/or spectroscopic platforms from the laboratory and pre-clinical level to the clinical level. Applications are sought from multi-disciplinary, multi-institutional research teams. After the awards, successful teams will become Centers that will be organized into an interactive network. The network will be called the "Network for Translational Research: Optical Imaging" (NTR). The purpose of NTR is to develop, optimize, and validate imaging technology platforms and methods so that they can enter single or multi-site clinical trials and eventually be incorporated into clinical practice. Applicants responding to this FOA must identify a specific cancer-relevant clinical goal and propose to develop and validate at least one multimodal imaging platform, as defined in this FOA, to address this clinical goal.

  • Letters of Intent Receipt Date: December 24, 2007
  • Set-aside funds: $4.8M per year, $24M over 5 years; approximately 4 awards

See full description in NIH Guide: RFA-CA-08-002

Back to top

PA-07-356: Clinical Cancer Therapy and Prevention Research (R01)

  • Release Date: April 16, 2007

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 301-451-2651

The National Cancer Institute (NCI) is seeking research project (R01) applications to conduct translational, clinical, therapeutic, and preventive studies and trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer genetics, cancer epigenetics, and cancer biology, coupled with the development of new anti-cancer agents, into innovative cancer intervention studies and trials. The overall aims of this funding opportunity announcement (FOA) are two-fold: (1) to stimulate the development of innovative cancer prevention and therapy clinical trials with or without laboratory correlative studies; and (2) to support innovative correlative laboratory studies retrospectively and prospectively linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.

No set-aside

See full description in NIH Guide: PA-07-356

Back to top

PA-07-041 and PA-07-042: Image-Guided Cancer Interventions (STTR [R41/R42] & SBIR [R43/R44])

  • Release Date: February 20, 2007
  • Application Receipt Date: Multiple dates, see announcements.

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 301-451-2651

    Laurence P. Clarke, Ph.D.
    Email: lclarke@mail.nih.gov
    Phone: 301-435-9190

These Funding Opportunity Announcements (FOA) support the development and clinical validation of systems for image-guided interventions (IGIs) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; the validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

See full description in NIH Guide: STTR (R41/R42) PA-07-041; SBIR (R43/44) PA-07-042

Back to top

Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01) (PAR-10-169)

  • Release Date: February 12, 2007
  • Application Receipt Date: Multiple dates, see announcement.
  • Expiration Date: May 8, 2013

  • Contacts:
    Houston Baker, Ph.D.
    Phone: 240-276-5908
    Email: bakerhou@mail.nih.gov

    James Deye, Ph.D.
    Phone: 240-276-5705
    Email: deyej@mail.nih.gov

This Funding Opportunity Announcement (FOA) issued by the Cancer Imaging and Radiation Research Programs of the National Cancer Institute (NCI), National Institutes of Health (NIH), encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either animal or human in vivo imaging, image guided, and/or spectroscopic systems and methods designed to solve targeted cancer problems for cancer research, clinical trials, and/or clinical practice. The partners on each application will establish an inter-disciplinary, multi-institutional research team to work in a strategic alliance to implement a coherent strategy to develop and translate the proposed system or methods with potential for significant impact on preclinical, single, or multisite clinical studies. Partnerships must include at least one lead academic and one lead industrial organization large or small among their numbers. For either preclinical or clinical research, funding may be requested for limited additional copies of prototype systems and methods in order to optimize and validate them across different platforms and/or research sites. Each partnership is encouraged to plan to solve its choice of targeted cancer problem within the five year funding period. This FOA supports clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. It will not support commercial production.

Note that this revised PAR has provided: (a) a revised definition of translational research consistent with the NCI Translational Research Working Group (TRWG) recommendations, (b) a definition of innovation within the context of the TRWG recommendation, (c) examples of translational research for current commercial and next generation of imaging platforms and (d) modified review criteria within the context of the TRWG recommendations. The intent of the revised PAR is to encourage applications with a strong translational research focus. Note that investigators interested in the creation of research resources to assist in validation of imaging technologies are encouraged to explore collaboration with research networks (U01, U54) consistent with the PAR goals.

See NIH Guide Announcement http://grants.nih.gov/grants/guide/pa-files/PAR-10-169.html

Back to top

RFA-CA-07-505: The American College of Radiology Imaging Network (ACRIN) (Limited Competition U01)

  • Release Date: February 09, 2007
  • Application Receipt Date: April 10, 2007

  • Contacts:
    Barbara A. Galen, MSN, CRNP, CNMT
    Phone: 301-594-5225
    Email: bgalen@mail.nih.gov

The Cancer Imaging Program, Division of Cancer Diagnosis and Treatment, the National Cancer Institute (NCI), invites applications for a limited competition Request for Applications (RFA) for the continued support of a unique, multi-center imaging network — the American College of Radiology Imaging Network (ACRIN; hereafter referred to as the "Network"). The overall objective of this limited competition RFA is to improve the use of imaging in cancer research and cancer care management through further support for the activities of the Network. The Network should continue to focus on investigator-initiated research involving key aspects of imaging technology assessment in oncology. Eligible organizations include the current recipients of the ACRIN awards, which are the American College of Radiology-Philadelphia Headquarters and the Brown University-Biostatistics and Data Management Center. The eligible applicants are expected to submit two linked applications (Network Headquarters application and Biostatistics and Data Management Center application). Both applications will be reviewed together and will receive a single score.

URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-505.html

Back to top

PAR-06-406: In Vivo Cellular and Molecular Imaging Centers (ICMICs)[P50]

  • Release Date: May 09, 2006
  • Application Receipt Date: August 16, 2006; August 16, 2007
  • Expiration Date: August 17, 2007

  • Contacts:
    Anne E. Menkens, NCI
    Phone: 301-496-9531
    Email: menkensa@mail.nih.gov

This is a reissue of PAR-04-069, which was previously released February 27, 2004.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the progress in molecular imaging as the basis for the extraordinary, non-invasive and quantitative analytical tools useful in the diagnosis and treatment of cancer as well as in the laboratory environment to interrogate biological pathways relevant to cancer. The Cancer Imaging Program of the NCI solicits new or competing applications for P50 Research Center Grants for In Vivo Cellular and Molecular Imaging Centers (ICMICs). The program will fund the 5-year P50 ICMIC grants to support interdisciplinary scientific teams conducting cutting-edge cancer molecular imaging research with clinical relevance. ICMIC funding is designed to: (1) support unique core facilities; (2) enable the awardees to initiate pilot research in new promising directions; and (3) provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging.

See full description in NIH Guide: PAR-06-406

Back to top

PA-06-398: Novel Technologies For In Vivo Imaging (R21/R133)

This Program Announcement (PA) replaces PA-04-095.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits Phased Innovation (R21/R33) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality.

See full description in NIH Guide: PA-06-398

What is the R21 grant mechanism?
What is the R33 grant mechanism?

Back to top

PA-06-399: Novel Technologies For In Vivo Imaging (R33)

This Program Announcement (PA) replaces PA-04-095.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R33 (Phase II, Developmental) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and/or treatment of various diseases.

See full description in NIH Guide: PA-06-399

What is the R33 grant mechanism?

Back to top

PA-06-371: In Vivo Cancer Imaging Exploratory/Developmental Grants (R21)

  • Release Date: April 27, 2006
  • Application Receipt Date: standard dates

  • Contacts:
    Anne E. Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-435-9024

The Cancer Imaging Program (CIP) of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) applications that articulate exploratory/developmental research focused on in vivo cancer imaging. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial development and/or feasibility testing of high impact concepts. Topics considered responsive to this Program Announcement will cover the entire spectrum of in vivo cancer imaging research, from basic discovery of new cancer imaging agents and technologies, through pre-clinical testing and validation, to the early feasibility testing of those novel agents and technologies in small clinical trials. The applicant may request a project period of up to two years with a combined budget for direct costs of up $275,000 for the two year period.

No set-aside

See full description in NIH Guide: PA-06-371

Back to top

RFA-CA-07-004: Small Animal Imaging Resource Program (U24) (NCI)

  • Release Date: April 10, 2006
  • Application Receipt Date: May 18, 2006

  • Contacts:
    Barbara Croft, Ph.D.
    Email: croftb@mail.nih.gov
    Phone: 301-435-9025

Letter of Intent Receipt Date: April 18, 2006

The NCI invites applications from extramural investigators for Small Animal Imaging Resources (SAIRs). These grants will support: (a) shared imaging resources to be used by cancer investigators; (b) research related to small animal imaging technology or methodology; and (c) training of both professional and technical support personnel interested in the science and techniques of small animal imaging. Small Animal Imaging Resources (SAIRs) will enhance capabilities for conducting basic, translational, and clinical cancer research relevant to the mission of the NCI. Major goals of this initiative are to increase efficiency, synergy, and innovation of such research and to foster research interactions that cross disciplines, approaches, and levels of analysis. Building and strengthening such links holds great potential for better understanding cancer, and ultimately, for better treatment and prevention. The application implements the new multiple-PI policy.

See full description in NIH Guide: RFA-CA-07-004

Back to top

PA-06-032: An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)

  • Release Date: November 12, 2005
  • Application Receipt Date: April 1, August 1, November 2

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov

    Laurence P. Clarke, Ph.D.
    Email: lclarke@mail.nih.gov

The purpose of this funding opportunity is to support the development and clinical validation of systems for image-guided interventions (IGI) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multi-site clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

See full description in NIH Guide: PA-06-032

Back to top

PA-06-031: Image-Guided Cancer Interventions (STTR [R41/R42])

  • Release Date: November 12, 2005
  • Application Receipt Date: April 1, August 1, November 2, 2006

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov

    Laurence P. Clarke, Ph.D.
    Email: lclarke@mail.nih.gov

The purpose of this funding opportunity is to support the development and clinical validation of systems for image-guided interventions (IGI) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multi-site clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

See full description in NIH Guide: PA-06-031

Back to top

NOT-OD-05-060: Small Business Innovation Research Program Request for Proposals

  • Release Date: September 06, 2005
  • Application Receipt Date: November 4, 2005

  • Contacts:
    Barbara Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-435-9025

    Anne Menkens, Ph.D.
    Email: menkensa@mail.nih.gov
    Phone: 301-496-9531

Small Business Innovation Research Program (NOT-OD-05-060) Request for Proposals

The purpose of this notice is to (1) announce the issuance of the SOLICITATION OF THE PUBLIC HEALTH SERVICE FOR SMALL BUSINESS INNOVATION RESEARCH CONTRACT PROPOSALS (PHS 2006-1); and (2) inform the public about the opportunities that the SBIR program offers to small business concerns as well as to scientists at research institutions. The National Cancer Institute has announced 21 research topics, among them #207 Synthesis Modules for Radiopharmaceutical Production, #208 Targetry Systems for Production of Research Radionuclides and #223 Synthesis and High-throughput Screening of in vivo Cancer Molecular Imaging Agents. Any small business concern that intends to submit an SBIR contract proposal under this Solicitation should provide the appropriate contracting officer(s) with early, written notice of its intent, giving its name, address, telephone, and topic number(s). If a topic is modified or canceled before this Solicitation closes, only those companies that have expressed such intent will be notified.

National Cancer Institute (NCI) contracting officer:
Ms. Mary Landi-O’Leary
Phone: (301) 435-3807
Fax: (301) 480-0309
ml186r@nih.gov

See full Notice in NIH Guide: NOT-OD-05-060

Back to top

Supplements for Research on Image-Guided Interventions in SPOREs and Cancer Centers (IGI Supplemental Awards)

  • Release Date: September 06, 2005
  • Application Receipt Date: June 1, 2005

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 301-451-2651

SUPPLEMENTS FOR RESEARCH ON IMAGE-GUIDED INTERVENTIONS IN SPORES AND CANCER CENTERS (IGI SUPPLEMENTAL AWARDS) (NCI)

Letter of intent: May 1, 2005

IGI Supplemental Awards are intended to facilitate the development, validation, and optimization of oncologic IGI methods, as well as the identification of promising, clinically safe and feasible new oncologic IGIs that warrant subsequent multi-center clinical investigations. Collaboration between investigators of the SPORE or Cancer Center and their basic science and engineering colleagues, both within and outside of the institution, and industry when appropriate is encouraged. The inclusion of minorities or individuals from underserved populations as participants in the study and the involvement of a junior clinical investigator in its design and execution are encouraged. Junior investigators with appropriate qualifications are eligible to serve as Principal Investigators. Eligible applicants include all SPORE investigators and Cancer Center investigators, their co-investigators, and clinical and basic scientists in other departments of the institution.

URL: http://www3.cancer.gov/cancercenters/announcements/IGI_Award.pdf

Back to top

PAR-05-114: Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants

  • Release Date: May 20, 2005
  • Application Receipt Date: August 9, December 9, April 9, 2005 through 2008

  • Contacts:
    Lalitha Shankar, M.D.
    Email: shankarl@mail.nih.gov
    Phone: 301-495-9531

    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 301-451-2651

The goal of this program is to fund applications focused on the following areas of research: 1) Phase I or II clinical trials of novel imaging-agents to assure their safety and efficacy, so that further evaluations of the clinical potentials of these agents can proceed; 2) Feasibility studies in image-guided intervention, to establish treatment parameters and early therapeutic efficacy for these methods; and/or 3) Clinical feasibility or "proof-of-principle" studies or clinical trials to demonstrate potential efficacy of promising discoveries in imaging or image-guided therapy methodologies or technologies. Investigators may apply for a maximum of 2 years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year. The anticipated number of awards is three to six per year.

See full description in NIH Guide: PAR-05-114

Back to top

PAR-04-155: Quick Trials for Novel Cancer Therapies: Exploratory Grants

This PA is intended to provide investigators with rapid access to support for pilot, Phase I, and Phase II cancer clinical trials as well as patient monitoring and laboratory studies. The focus of this QUICK-TRIAL PA is on translational research in new agent or device development to ensure the timely exploitation of new cancer therapeutic. This PA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and accelerated peer review with the goal of issuing new awards within six months of application receipt. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy and rapid development and application of novel clinical cancer therapies including image guided therapeutic procedures. Investigators may apply for a maximum of two years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year.

Application Receipt Dates: December 9, 2004; April 9, 2005; August 9, 2005; December 9, 2005; April 9, 2006; August 9, 2006; December 9, 2006; April 9, 2007; August 9, 2007; December 9, 2007

See full description in NIH Guide: PAR-04-155

Back to top

PA-04-095: Novel Technologies for In Vivo Imaging (R21/R33)

This Program Announcement (PA) replaces PAR-03-124.

The NCI invites applications for the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality.

See full description in NIH Guide: PA-04-095

What is the R21 grant mechanism?
What is the R33 grant mechanism?

Back to top

PA-04-094: Novel Technologies for In Vivo Imaging (SBIR/STTR)

This Program Announcement (PA) replaces PAR-03-125.

The NCI Cancer Imaging Program and Radiation Research Program, and the NIEHS, NIDDK, and NINDS invite applications for the development and delivery of novel in vivo image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy. Applications may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions and treatments of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality.

See full description in NIH Guide: PA-04-094

Back to top

PAR-04-069: In Vivo Cellular and Molecular Imaging Centers (ICMICS)

  • Release Date: February 27, 2004
  • Application Receipt Date: July 22, 2004; July 21, 2005

  • Contacts:
    Anne E. Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-435-9024

The Cancer Imaging Program, Division of Cancer Diagnosis and Treatment of the National Cancer Institute (NCI), invites applications for new or competing P50 Research Center Grants for In Vivo Cellular and Molecular Imaging Centers (ICMICs). This initiative is designed to capitalize on the extraordinary opportunity for molecular imaging to have an impact on the diagnosis and treatment of cancer patients non-invasively and quantitatively. Molecular imaging technologies can provide valuable laboratory tools for the interrogation of biological pathways relevant to cancer, as well as to provide imaging agents and technologies that will be directly utilized in the clinic. The 5-year P50 ICMIC grants described in this PAR are designed to bring together interdisciplinary scientific teams to lead the nation in cutting-edge cancer molecular imaging research with clinical relevance, provide unique core facilities to support oncology imaging research, provide flexibility to respond to exciting pilot research opportunities, and provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging. The P50 mechanism will promote coordination, interrelationships and scientific synergy among the research components and resources, leading to a highly integrated imaging center.

Letter of Intent Receipt Date(s): June 22, 2004; June 21, 2005

See full description in NIH Guide: PAR-04-069

Back to top

PA-04-063: An SBIR/STTR Initiative for Image-Guided Cancer Interventions

  • Release Date: February 17, 2004
  • Application Receipt Date: April 1, August 1, and December 1

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 301-451-2651

The purpose of this Program Announcement (PA) is to support the development and clinical validation of systems for image-guided interventions (IGI) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multi-site clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

SBIR set-aside

See full description in NIH Guide: PA-04-063

What is SBIR?
What is STTR?

Back to top

RFA: CA-05-007: Application of Emerging Technologies for Cancer Research (SBIR/STTR)

  • Release Date: January 07, 2004
  • Application Receipt Date: March 10, 2004; June 17, 2004; October 18, 2004

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

The NCI invites applications for research projects to evaluate the usefulness of emerging technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements, as well as be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus.

Letter of Intent Receipt Date(s): February 10, 2004; May 17, 2004; September 17, 2004

See full description in NIH Guide: RFA: CA-05-007

Back to top

NCI RFA: CA-05-006: Innovative Technologies for Molecular Analysis of Cancer (SBIR/STTR)

  • Release Date: January 07, 2004
  • Application Receipt Date: March 10, 2004; June 17, 2004; October 18, 2004

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

The NCI invites applications for research projects proposing the development of highly innovative cancer relevant technologies, encompassing methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Technology is distinct from resources such as databases, reagents, and tissue repositories.

Letter of Intent Receipt Date(s): February 10, 2004; May 17, 2004; September 17, 2004

See full description in NIH Guide: RFA: CA-05-006

Back to top

PA-04-045: In Vivo Cancer Imaging Exploratory/Developmental Grants (R21)

  • Release Date: December 24, 2003
  • Application Receipt Date: February 1, June 1, and October 1

  • Contacts:
    Anne E. Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-435-9024

The Cancer Imaging Program (CIP) of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) applications that articulate exploratory/developmental research focused on in vivo cancer imaging. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial development and/or feasibility testing of high impact concepts. Topics considered responsive to this Program Announcement will cover the entire spectrum of in vivo cancer imaging research, from basic discovery of new cancer imaging agents and technologies, through pre-clinical testing and validation, to the early feasibility testing of those novel agents and technologies in small clinical trials. The applicant may request a project period of up to two years with a combined budget for direct costs of up $275,000 for the two year period.

No set-aside

See full description in NIH Guide: PA-04-045

Back to top

PA-04-046: Clinical Cancer Therapy and Prevention Research

  • Release Date: December 24, 2003
  • Application Receipt Date: February 1, June 1, and October 1

  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 301-451-2651

The NCI is seeking R01 applications to conduct translational, clinical, therapeutic, and preventive studies/trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer biology and the development of new anti-cancer agents into innovative cancer intervention studies/trials. The overall aims of this renewed PA are two-fold: (1) to stimulate development of innovative therapeutic/preventive clinical trials with or without laboratory correlative studies (2) to support innovative correlative laboratory studies linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.

No set-aside

See full description in NIH Guide: PA-04-046

Back to top

NCI/NIH RFA: CA-04-011: Small Animal Imaging Resource Programs

  • Release Date: October 02, 2003
  • Application Receipt Date: December 18, 2003

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

The National Cancer Institute (NCI) invites applications from extramural investigators for Small Animal Imaging Resource Programs (SAIRPs). These grants will support (a) shared imaging research resources to be used by cancer investigators, (b) research related to small animal imaging technology, and (c) training of both professional and technical support personnel interested in the science and techniques of small animal imaging.

Letter of Intent Receipt Date(s): November 18, 2003

See full description in NIH Guide: NCI/NIH RFA: CA-04-011

Back to top

PAR-03-157: Industry-Academic Partnerships for Development of Biomedical Imaging Systems and Methods that are Cancer Specific (R21)

  • Release Date: July 29, 2003
  • Application Receipt Date: November 19, 2003; November 17, 2004

  • Contacts:
    Guoying Liu, Ph.D.
    Email: liug@mail.nih.gov
    Phone: 301-594-5220

The National Cancer Institute (NCI) invites applications for the pursuit of industry-academic partnerships for development of biomedical imaging systems and methods that are cancer specific. Support for the exchange of scientists between industry and academia can be requested under this initiative.

The goals of this initiative are to

1) Provide grants to help establish and/or expand industry-academic partnerships for development of biomedical imaging systems and methods that are cancer specific whether or not preliminary data or a history of prior collaborations have been established;

2) Support partnerships and pilot projects that may result in commercialization of imaging technologies;

3) Target partnerships that address high-risk/high-gain research and development of new approaches for early cancer detection, diagnosis, image-guided interventions, and assessment of drug therapy.

Letter of Intent Receipt Date(s): October 22, 2003; October 20, 2004

See full description in NIH Guide: PAR-03-157

What is the R21 grant mechanism?

Back to top

PAR-03-124: Novel Technologies for In vivo Imaging (R21/R33)

  • Release Date: May 19, 2003
  • Application Receipt Date: July 21, 2003 and November 19, 2003

  • Contacts:
    Houston Baker, Ph.D.
    Email: bakerhou@mail.nih.gov

PAR-03-124 has been replaced by PA-04-095, which uses Regular Receipt Dates: June 1, October 1, and February 1.

The National Cancer Institute (NCI) and the National Institute for Biomedical Imaging and Bioengineering (NIBIB) invite applications for the development and delivery of novel image acquisition or enhancement technology and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the proof of feasibility, development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and secondarily to facilitate limited evaluation studies to show proof of concept and functionality.

Letter of Intent Receipt Date(s): June 23, 2003 and October 22, 2003

See full description in NIH Guide: PAR-03-124
See full description in NIH Guide: PA-04-095

Back to top

PAR-03-125: Novel Technologies for In vivo Imaging (SBIR/STTR)

  • Release Date: May 19, 2003
  • Application Receipt Date: July 21, 2003 and November 19, 2003

  • Contacts:
    Houston Baker, Ph.D.
    Email: bakerhou@mail.nih.gov

PAR-03-125 has been replaced by PA-04-094, which uses Regular Receipt Dates: August 1, December 1, and April 1.

The National Cancer Institute (NCI), the National Institute of Environmental Health Sciences (NIEHS), the National Institute for Biomedical Imaging and Bioengineering (NIBIB) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications for the development and delivery of novel image acquisition or enhancement technology and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the proof of feasibility, development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions and treatment of various diseases, and secondarily to facilitate limited evaluation studies to show proof of concept and functionality.

Letter of Intent Receipt Date(s): June 23, 2003 and October 22, 2003

See full description in NIH Guide: PAR-03-125
See full description in NIH Guide: PA-04-094

Back to top

NOT-CA-03-026: Instrumentation Grants for Imaging Equipment Used in Clinical Trials: Administrative Supplements to Cancer Center Support Grants (P30)

  • Release Date: April 11, 2003
  • Application Receipt Date: June 20, 2003

  • Contacts:
    Guoying Liu, Ph.D.
    Email: liug@mail.nih.gov

The National Cancer Institute (NCI) is announcing the availability of administrative supplemental funds for NCI-funded cancer center grantees (P30s) (domestic only). The primary purpose of this initiative is to provide matching funds to assist in the acquisition of dedicated clinical research imaging equipment, or significant upgrades to existing clinical research imaging equipment (software and/or hardware), in order to optimize the use of imaging as a biomarker in Phase 1 and 2 oncologic trials. The initiative is part of a continuing effort to stimulate and strengthen the use of imaging techniques in cancer research. NCI-funded cancer centers possess the infrastructure, organization, leadership, and integrated multidisciplinary research objectives that enable them to build and incorporate new image technologies into cancer clinical trials.

See full description in NIH Guide: NOT-CA 03-026

Back to top

NOT-CA-03-016: Administrative Supplement Requests: Instrumentation Grants for Small Animal Imaging Equipment

  • Release Date: April 11, 2003
  • Application Receipt Date: June 20, 2003

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

The National Cancer Institute (NCI) is announcing the availability of administrative supplemental funds for NCI-funded R24, P30, P50, U01, and U54 grantees (domestic only). This administrative supplemental initiative is intended to assist the grantees in creating or extending capabilities in small animal imaging. The initiative is part of a continuing effort to stimulate and strengthen research in small animal imaging techniques and to increase the use of small animal imaging techniques in cancer research. The Instrumentation Grants For Small Animal Imaging Equipment (Administrative Supplements) will provide dedicated funds to buy or upgrade imaging equipment for small animals, emphasizing those modalities that can provide biochemical, molecular, genetic or pharmacological information in vivo.

See full description in NIH Guide: NOT-CA 03-016

Back to top

NCI NOT-CA-03-001: Notice of Limited Competition Request for Competitive Request for Competitive Renewal Applications: ACRIN-Biomedical Imaging (U01)

  • Release Date: December 19, 2002

  • Contacts:
    Barbara A. Galen, M.S.N., C.R.N.P.
    Email: bgalen@mail.nih.gov

The NCI is requesting competing renewal applications from the American College of Radiology Imaging Network (ACRIN), funded originally through RFA CA-97-020. This will continue a unique ongoing project at its current level and scope to best serve the oncology and imaging science communities. This is particularly important now because ACRIN is currently conducting several ongoing imaging clinical trials critical to the goals of the NCI. The combination of imaging with minimally invasive diagnosis and treatment will enhance clinical practice by limiting disfigurement, trauma and expense.

See full description in NIH Guide: NCI NOT-CA-03-001

Back to top

RFP: N01-CM-37008: Re-Issue - Early Clinical Trials of Imaging Agents

  • Release Date: November 26, 2002

  • Contacts:
    Kathy Giuliano, Contract Specialist
    Phone: (301) 435-3821
    Fax: (301) 402-6699
    Email: kg109o@nih.gov

    MaryAnne Golling, Contracting Officer
    Phone: (301) 435-3819
    Fax: (301) 402-6699
    Email: mg345x@nih.gov

The Cancer Imaging Program (CIP), Division of Cancer Diagnosis and Treatment (DCTD), National Cancer Institute (NCI) plans to develop contracts to support Phase 1 (Safety) and Phase 2 (Preliminary Clinical Efficacy) clinical trials of promising imaging agents. These clinical trials will be used to rapidly evaluate the safety and diagnostic imaging capabilities of promising imaging probes, ligands, radiopharmaceuticals, and contrast agents that are of interest to NCI. The Safety and Preliminary Clinical Efficacy Imaging Clinical Trials contracts will create an infrastructure poised to rapidly evaluate molecularly-targeted imaging agents used to assess therapeutic anticancer agents on their molecular targets and determine clinically relevant correlates. The objectives of this program are: to rapidly conduct clinical trials necessary to assess the safety of promising imaging agents; to rapidly conduct clinical trials necessary to assess the diagnostic imaging capabilities and preliminary efficacy of promising imaging agent to characterize the molecular interactions of new molecular imaging agents with their targets through biopsies, assays, and other appropriate technologies and correlate those effects with clinically-relevant endpoints; to develop new scientific insights into molecular pathways and determinants of the relationship of the targeted imaging agents to therapeutic drug response. Major emphasis shall be on imaging agents which are found to be safe and provide important structural, metabolic, or molecular imaging data which will be important and useful in the management of patients with cancer. These Phase 1 and Phase 2 clinical trials will obtain the necessary data to fulfill the Food and Drug Administration (FDA) criteria to eventually become an approved and potentially marketable imaging agent for specific imaging indications. The studies will explore promising imaging agents, and require rapid initiation, completion, and data reporting. These contracts will also require the ability to implement correlative studies validating the localization of the investigational imaging agents on their molecular target in tumors. Imaging agents may originate from investigators not affiliated with clinical sites. The Government anticipates that five (5) contracts will be awarded on an incrementally funded basis for five years. The size of each trial might vary depending on consultation with the FDA for each specific agent. The typical size for each Safety trail will be approximately 10 patients. The typical size for each Preliminary Clinical Efficacy trail is estimated to be 25 patients. NAICS Code No. 621512 with a size standard of $5.Million.

See full description: RFP: N01-CM-37008

Back to top

RFA: CA-03-002: Network for Translational Research: Optical Imaging

  • Release Date: August 27, 2002
  • Application Receipt Date: January 21, 2003

  • Contacts:
    Houston Baker, Ph.D.
    Email: bakerhou@mail.nih.gov

Change of Receipt Date

The Cancer Imaging Program (CIP), of the Division of Cancer Treatment and Diagnosis (DCTD) solicits applications for cooperative agreement (U54) awards to establish a Specialized Research Resource Center that will participate as a member of a network of inter-disciplinary, inter- institutional research teams for the purpose of supporting translational research in optical imaging and/or spectroscopy in vivo. The network will operate under the guidance of a Steering Committee (SC). The goal is to organize a consortium with flexibility in scope, funding, and incentives to encourage inter- and intra-team collaborations on translational cancer research. The objective is to accelerate the pace of translational research by developing a consensus process to improve methods for system integration, optimization and validation of next-generation in vivo optical imaging and/or spectroscopy methods and technologies, including contrast agents. The research scope includes feasibility studies for the detection of pre-cancerous lesions, cancer detection and diagnosis, and measurement or prediction of response to therapy.

Letter of Intent Receipt Date(s): December 17, 2002

See full description in NIH Guide: RFA: CA-03-002

Back to top

PAR-01-101: Development of Novel Imaging Technologies (Phased Innovation Award)

  • Release Date: May 29, 2001
  • Application Receipt Date: July 16, 2001 and March 18, 2002, and July 16, 2002

  • Contacts:
    Houston Baker, Ph.D.
    Email: hb4s@nih.gov

    Laurence Clarke, Ph.D.
    Email: lclarke@mail.nih.gov

The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to develop novel in vivo image acquisition or enhancement methods, and incorporate limited pilot or feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the development of novel imaging technologies for early detection, screening, diagnosis, and image guided treatment of cancer and other diseases. The intent is to stimulate (a) the development of innovative image acquisition and enhancement methods, including high risk/high gain research on technologies that exploit our knowledge of the molecular basis of cancer or other disease, and (b) the integration of these emerging technologies with traditional imaging methods for more effective solutions for health care delivery. A phased innovation award mechanism (R21/R33) is proposed that is suitable for supporting imaging technology development. Applications from academia, industry, and independent research organizations are encouraged. Modifications to this reissued Program Announcement include support for a limited number of system prototypes for pilot or feasibility evaluations using either pre-clinical models or clinical studies. Applicants considering developments for ex vivo or in vitro molecular imaging are encouraged to read announcements PAR-01-105 and PAR-01-107 for Innovative Technologies for the Molecular Analysis of Cancer, listed under NCI Initiatives. Small business applicants with in vivo imaging interests are encouraged to apply under announcement, PAR-01-102.

Letter of Intent Receipt Date(s): June 11, 2001, February 11, 2002 and June 11, 2002

No set aside

See full description in NIH Guide: PAR-01-101

Back to top

PA-01-030: Exploratory/Developmental Grants for Diagnostic Cancer Imaging (R21s)

  • Release Date: December 08, 2000
  • Application Receipt Date: February 1, June 1, and October 1

  • Contacts:
    Anne E. Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-435-9024

Inclusion of Additional Receipt Dates NOT-CA-03-034
Inclusion of Additional Receipt Dates NOT-CA-02-023

The Biomedical Imaging Program (CIP), of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) grants that articulate highly innovative research concepts in diagnostic cancer imaging. Within each area of importance in imaging, there exists a need for innovative and creative approaches leading to new avenues of research. One way to encourage research into high risk/high impact areas is to provide investigators with the initial resources required to accomplish feasibility and pilot testing of innovative ideas. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial feasibility testing of high risk/high impact concepts and, if the concepts are viable, for the generation of experimental preliminary data. This would render the investigators competitive for continued funding through other NIH research award mechanisms, thus potentially leading to the establishment of new research programs in areas that might have previously remained unexplored.

No set aside

See full description in NIH Guide: PA-01-030

Back to top

NCI/CIP RFA: CA-01-012: REISSUE: Small Animal Imaging Resource Programs (SAIRPs)

  • Release Date: October 19, 2000
  • Application Receipt Date: November 28, 2000

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

Support both: (a) inter-disciplinary shared imaging research resources to be used by cancer investigators and (b) research related to small animal imaging technology.

Letter of Intent Receipt Date(s): October 19, 2000

$5.9 M FY01
$20 M Total

See full description in NIH Guide: NCI/CIP RFA: CA-01-012

Back to top

RFA: CA-01-010: Planning Grants: In Vivo Cellular and Molecular Imaging Centers (Pre-ICMICs: P20 Center Grants)

  • Release Date: May 01, 2000

  • Contacts:
    Anne E. Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-435-9024

Grants are designed to support inter-disciplinary centers for functional imaging research (imaging sciences, chemistry, radiopharmaceutical chemistry, cell and molecular biology, pharmacology, computer science and biomedical engineering).

See full description in NIH Guide: RFA: CA-01-010

Back to top

PAR-00-090: Development of Novel Imaging Technologies: (SBIR/STTR) Initiative

  • Release Date: April 27, 2000
  • Application Receipt Date: July 19, 2000 and March 16, 2001

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

    Laurence P. Clarke, Ph.D.
    Email: lclarke@mail.nih.gov
    Phone: 301-496-9531

The National Cancer Institute (NCI) invites applications on the development of novel image acquisition or enhancement methods, incorporating limited pilot or feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the development of novel imaging technologies for early detection, screening, diagnosis and image guided treatment of cancer and other diseases. The intent is to stimulate: (a) the development of highly innovative image acquisition and enhancement methods, including high risk/high gain research on technologies that exploit our knowledge of the molecular basis of cancer or other disease, and (b) the integration of these emerging technologies with traditional imaging methods for more effective solutions for health care delivery. A phased innovation award mechanism (R21/R33) is proposed that is more suitable for supporting imaging technology development. Applications from academia, industry and the use of the SBIR/STTR funding mechanisms are encouraged.

Letter of Intent Receipt Date(s): June 14, 2000 and February 9, 2001

No set aside

See full description in NIH Guide: PAR-00-090

Back to top

RFA: CA-01-001: Lung Imaging Database Resource for Imaging Research

  • Release Date: April 10, 2000
  • Application Receipt Date: July 14, 2000

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

The National Cancer Institute (NCI) invites applications from investigators who are interested in joining a consortium of institutions to develop the necessary consensus and standards for an image database resource and to construct a database of spiral computed tomography (CT) lung images. There is considerable interest in using spiral CT lung scanning for lung cancer screening for patients at high risk. Early detection and intervention may significantly reduce lung cancer mortality rates. The use of image processing methods may be an important adjunct to facilitate spiral CT lung cancer screening. Investigators developing image-processing algorithms need standardized databases with which to work. The generation of standardized databases requires the development of consensus on many issues related to database design, accessibility, metrics and statistical methods for evaluating image-processing algorithms. NCI therefore plans to establish a consortium of institutions, called the Lung Image Database Consortium (LIDC), to develop such consensus and the necessary database.

Set aside: $7M over five years, five academic sites.

Letter of Intent Receipt Date(s): June 9, 2000

See full description in NIH Guide: RFA: CA-01-001

Back to top

NCI: CIP/OWH: PA-99-082 / 083: Development and Testing of Digital Mammography Displays and Workstations (R0I/ SBIR/STTR)

  • Release Date: April 01, 1999
  • Application Receipt Date: Regular submission dates

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

Integrate hardware, software and psychophysics research to optimize displays for digital mammography.

No set aside

Funded Projects (TBA)

See full description in NIH Guide: PA-99-082
See full description in NIH Guide: PA-99-083

Back to top

RFA: CA-99-015 / PAR-99-149 (SBIR/STTR): Diagnostic Imaging and Guided Therapy in Prostate Cancer. Phased Innovation Award (R21/R33)

  • Release Date: October 20, 1998
  • Application Receipt Date: November 17, 1999

  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

Grants are designed to support the development, risk assessment, and application of improved imaging methods for the localization, biopsy and image guided biopsy or therapy of prostate cancer. Relevant investigations could include technology development, in vitro laboratory work, pre-clinical animal studies, or early feasibility testing in humans depending on the maturity of the methods proposed, or evaluation of the effects of age-associated changes and co-morbid conditions as they affect imaging diagnosis and treatment techniques.

Letter of Intent: National Cancer Institute and National Institute on Aging Receipt Date: October 20, 1999.

$1.6M FY 2000/ $13.6M Total

See full description in NIH Guide: RFA: CA-99-015
See full description in NIH Guide: PAR-99-149 (SBIR/STTR)

Back to top

RFA: CA-98-024: Development And Application of Imaging In Therapeutic Studies

  • Release Date: August 14, 1998

  • Contacts:
    Anne E. Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-435-9024

Support for development and application of labeled therapeutic agents as compounds for imaging studies, and/or metabolic markers of response to therapeutic agents.

Reviewed April 1999

$2.8 M FY99

$11.2 M Total

Funded Projects (TBA)

See full description in NIH Guide: RFA: CA-98-024

Back to top

RFA: CA-97-020: Cooperative Trials in Diagnostic Imaging

  • Release Date: August 22, 1997

  • Contacts:
    Anne E. Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-435-9024

Establish a single national Network of investigators to perform multi-institutional clinical trials in diagnostic imaging.

Contact ACRIN for proposed imaging protocols

Awarded to ACRIN

$3.0 M FY99/$23.0 M total

See full description in NIH Guide: RFA: CA-97-020

Back to top

PA-98-008: Exploratory/Developmental Grants for Diagnostic Cancer Imaging (R21s)

  • Release Date: August 01, 1997
  • Application Receipt Date: Regular submission dates

  • Contacts:
    Anne E. Menkens, Ph.D.
    Email: am187k@nih.gov
    Phone: 301-435-9024

Exploratory/development grants (high risk/high impact) that articulate highly innovative research concepts in diagnostic cancer imaging; i.e. generate experimental preliminary data for R01 funding for both new and established investigato

No set aside

Funded projects (TBA)

See full description in NIH Guide: PA-98-008

Back to top